Your browser doesn't support javascript.
loading
Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer's disease.
Colom-Cadena, Martí; Toombs, Jamie; Simzer, Elizabeth; Holt, Kristjan; McGeachan, Robert; Tulloch, Jane; Jackson, Rosemary J; Catterson, James H; Spires-Jones, Maxwell P; Rose, Jamie; Waybright, Lora; Caggiano, Anthony O; King, Declan; Gobbo, Francesco; Davies, Caitlin; Hooley, Monique; Dunnett, Sophie; Tempelaar, Robert; Meftah, Soraya; Tzioras, Makis; Hamby, Mary E; Izzo, Nicholas J; Catalano, Susan M; Durrant, Claire S; Smith, Colin; Dando, Owen; Spires-Jones, Tara L.
Afiliação
  • Colom-Cadena M; Centre for Discovery Brain Sciences and UK Dementia Research Institute, The University of Edinburgh, 1 George Square, Edinburgh, EH8 9JZ, UK.
  • Toombs J; Centre for Discovery Brain Sciences and UK Dementia Research Institute, The University of Edinburgh, 1 George Square, Edinburgh, EH8 9JZ, UK.
  • Simzer E; Centre for Discovery Brain Sciences and UK Dementia Research Institute, The University of Edinburgh, 1 George Square, Edinburgh, EH8 9JZ, UK.
  • Holt K; Centre for Discovery Brain Sciences and UK Dementia Research Institute, The University of Edinburgh, 1 George Square, Edinburgh, EH8 9JZ, UK.
  • McGeachan R; Centre for Discovery Brain Sciences and UK Dementia Research Institute, The University of Edinburgh, 1 George Square, Edinburgh, EH8 9JZ, UK.
  • Tulloch J; Centre for Discovery Brain Sciences and UK Dementia Research Institute, The University of Edinburgh, 1 George Square, Edinburgh, EH8 9JZ, UK.
  • Jackson RJ; Centre for Discovery Brain Sciences and UK Dementia Research Institute, The University of Edinburgh, 1 George Square, Edinburgh, EH8 9JZ, UK.
  • Catterson JH; MassGeneral Institute for Neurodegenerative Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02129, USA.
  • Spires-Jones MP; Centre for Discovery Brain Sciences and UK Dementia Research Institute, The University of Edinburgh, 1 George Square, Edinburgh, EH8 9JZ, UK.
  • Rose J; Centre for Discovery Brain Sciences and UK Dementia Research Institute, The University of Edinburgh, 1 George Square, Edinburgh, EH8 9JZ, UK.
  • Waybright L; Centre for Discovery Brain Sciences and UK Dementia Research Institute, The University of Edinburgh, 1 George Square, Edinburgh, EH8 9JZ, UK.
  • Caggiano AO; Scottish Brain Sciences, Edinburgh, EH12 9DQ, UK.
  • King D; Scottish Brain Sciences, Edinburgh, EH12 9DQ, UK.
  • Gobbo F; Centre for Discovery Brain Sciences and UK Dementia Research Institute, The University of Edinburgh, 1 George Square, Edinburgh, EH8 9JZ, UK.
  • Davies C; Centre for Discovery Brain Sciences and UK Dementia Research Institute, The University of Edinburgh, 1 George Square, Edinburgh, EH8 9JZ, UK.
  • Hooley M; Centre for Discovery Brain Sciences and UK Dementia Research Institute, The University of Edinburgh, 1 George Square, Edinburgh, EH8 9JZ, UK.
  • Dunnett S; Centre for Discovery Brain Sciences and UK Dementia Research Institute, The University of Edinburgh, 1 George Square, Edinburgh, EH8 9JZ, UK.
  • Tempelaar R; Centre for Discovery Brain Sciences and UK Dementia Research Institute, The University of Edinburgh, 1 George Square, Edinburgh, EH8 9JZ, UK.
  • Meftah S; Centre for Discovery Brain Sciences and UK Dementia Research Institute, The University of Edinburgh, 1 George Square, Edinburgh, EH8 9JZ, UK.
  • Tzioras M; Centre for Discovery Brain Sciences and UK Dementia Research Institute, The University of Edinburgh, 1 George Square, Edinburgh, EH8 9JZ, UK.
  • Hamby ME; Centre for Discovery Brain Sciences and UK Dementia Research Institute, The University of Edinburgh, 1 George Square, Edinburgh, EH8 9JZ, UK.
  • Izzo NJ; Scottish Brain Sciences, Edinburgh, EH12 9DQ, UK.
  • Catalano SM; Cognition Therapeutics Inc., Pittsburgh, PA, 15203, USA.
  • Durrant CS; Cognition Therapeutics Inc., Pittsburgh, PA, 15203, USA.
  • Smith C; Cognition Therapeutics Inc., Pittsburgh, PA, 15203, USA.
  • Dando O; Centre for Discovery Brain Sciences and UK Dementia Research Institute, The University of Edinburgh, 1 George Square, Edinburgh, EH8 9JZ, UK.
  • Spires-Jones TL; Centre for Clinical Brain Sciences and Sudden Death Brain Bank, University of Edinburgh, Edinburgh, EH16 4HB, UK.
Acta Neuropathol ; 147(1): 32, 2024 02 06.
Article em En | MEDLINE | ID: mdl-38319380
ABSTRACT
Synapse loss correlates with cognitive decline in Alzheimer's disease, and soluble oligomeric amyloid beta (Aß) is implicated in synaptic dysfunction and loss. An important knowledge gap is the lack of understanding of how Aß leads to synapse degeneration. In particular, there has been difficulty in determining whether there is a synaptic receptor that binds Aß and mediates toxicity. While many candidates have been observed in model systems, their relevance to human AD brain remains unknown. This is in part due to methodological limitations preventing visualization of Aß binding at individual synapses. To overcome this limitation, we combined two high resolution microscopy techniques array tomography and Förster resonance energy transfer (FRET) to image over 1 million individual synaptic terminals in temporal cortex from AD (n = 11) and control cases (n = 9). Within presynapses and post-synaptic densities, oligomeric Aß generates a FRET signal with transmembrane protein 97. Further, Aß generates a FRET signal with cellular prion protein, and post-synaptic density 95 within post synapses. Transmembrane protein 97 is also present in a higher proportion of post synapses in Alzheimer's brain compared to controls. We inhibited Aß/transmembrane protein 97 interaction in a mouse model of amyloidopathy by treating with the allosteric modulator CT1812. CT1812 drug concentration correlated negatively with synaptic FRET signal between transmembrane protein 97 and Aß. In human-induced pluripotent stem cell derived neurons, transmembrane protein 97 is present in synapses and colocalizes with Aß when neurons are challenged with human Alzheimer's brain homogenate. Transcriptional changes are induced by Aß including changes in genes involved in neurodegeneration and neuroinflammation. CT1812 treatment of these neurons caused changes in gene sets involved in synaptic function. These data support a role for transmembrane protein 97 in the synaptic binding of Aß in human Alzheimer's disease brain where it may mediate synaptotoxicity.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Alzheimer / Disfunção Cognitiva / Proteínas de Membrana Limite: Animals / Humans Idioma: En Revista: Acta Neuropathol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Alzheimer / Disfunção Cognitiva / Proteínas de Membrana Limite: Animals / Humans Idioma: En Revista: Acta Neuropathol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Reino Unido
...